Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | - |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 0.58 | 2.02 |
NAV | ₹39.49 | ₹64.68 |
Fund Started | 09 Nov 2018 | 18 Jun 2012 |
Fund Size | ₹5041.54 Cr | ₹3015.47 Cr |
Exit Load | Exit load of 1%, if redeemed within 15 days. | Exit load of 1% if redeemed within 1 month. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 14.55% | 13.06% |
3 Year | 27.55% | 16.62% |
5 Year | 19.22% | 14.25% |
1 Year
3 Year
5 Year
Equity | 0.00% | 98.01% |
Cash | 100.00% | 1.99% |
Equity
Cash
Top 10 Holdings | - |
|
Top 10 Holdings
Name | Assets |
---|---|
Veeva Systems Inc. | 3.04% |
West Pharmaceutical Services Inc | 2.81% |
Huntington Ingalls Industries Inc. (US) | 2.68% |
Brown-Forman Corp | 2.66% |
Allegion PLC | 2.47% |
Zimmer Biomet Holdings | 2.46% |
Microchip Technology Inc. (USA) | 2.44% |
Pfizer INC | 2.42% |
Monolithic Power Systems Inc. | 2.42% |
Corteva Inc. | 2.41% |
Name | Swapnil P Mayekar | Ritesh Lunawat |
Start Date | 14 Jul 2022 | 28 Dec 2020 |
Name
Start Date
Description | The Scheme seeks returns by investing in units of Motilal Oswal Nasdaq 100 ETF. | The investment objective of ICICI Prudential US Bluechip Equity Fund is to provide long term capital appreciation to investors by primarily investing in equity and equity related securities of companies listed on recognized stock exchanges in the United States of America. The Scheme shall also invest in ADRs/GDRs issued by Indian and foreign companies. |
Launch Date | 09 Nov 2018 | 18 Jun 2012 |
Description
Launch Date